A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

Quincy Jones, who died at 91 in November 2024, had seven children: Jolie, Rachel, Martina, Quincy III, Kidada, Rashida and ...

Researchers found that treating precancerous pancreatic lesions with experimental KRAS inhibitors slowed tumor development ...

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors.

A month has gone by since the last earnings report for Exelixis (EXEL). Shares have lost about 2.8% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent ...

Depleting a clotting protein from the liver may help slow pancreatic cancer, according to a new study conducted by a team of researchers at the Indiana University Melvin and Bren Simon Comprehensive ...

HIGHLIGHTS Amplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conferenceData showing narmafotinib activity in preclinical ...

How can I deliver care not just to the 100,000 patients who might have cancer but to the 500,000 patients who may be at risk of cancer?” That question is shaping the early tenure of Anirban Maitra, MD ...

Namodenoson (CF102), an investigational small-molecule A3 adenosine receptor (A3AR) agonist, has demonstrated favorable ...

Kestrel Therapeutics Inc. (“Kestrel” or the “Company”), a clinical stage biotechnology company developing next-generation small-molecule inhibitors targeting mutant KRAS, today announced that the U.S.